Jazz Pharmaceuticals AI Stock Analysis
Want to see JAZZ full AI Analyst Report?
Jazz Pharmaceuticals (JAZZ) AI Stock Analysis
Jazz Pharmaceuticals
(NASDAQ:JAZZ)
The score is driven primarily by strong cash flow generation and very high gross margins, supported by a strongly positive earnings update with raised 2026 guidance and encouraging Ziihera launch indicators. These positives are tempered by elevated leverage and earnings volatility, while the technical picture is mixed and valuation is stretched with a high P/E and no dividend support.
Jazz Pharmaceuticals Key Performance Indicators (KPIs)
Neroscience Revenue BreakdownHighlights revenue generated from neuroscience products, indicating the company's strength and focus in treating neurological disorders, and potential growth in this specialized market.
Jazz’s neuroscience mix has structurally shifted: legacy Xyrem has collapsed while Xywav has scaled to become the primary growth engine, effectively replacing lost oxybate revenue and underpinning management’s raised guidance and double‑digit Xywav outlook for 2026. Epidiolex is a steady, expanding second pillar with lifecycle initiatives that can sustain upside. Sativex and Sunosi are now immaterial. Watch risks: potential oxybate generics and rising royalty-driven margin pressure plus higher SG&A/R&D could temper profit leverage even as top-line momentum accelerates.
Jazz Pharmaceuticals (JAZZ) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $15.39B
- Dividend Yield
- ―
- Average Volume (3M)
- 878.88K
- Price to Earnings (P/E)
- 67.3
- Beta (1Y)
- 0.53
- Revenue Growth
- 13.48%
- EPS Growth
- ―
- Country
- US
- Employees
- 2,890
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Jazz Pharmaceuticals Business Overview & Revenue Model
Company Description
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopat...
How the Company Makes Money
Jazz Pharmaceuticals makes money primarily by selling prescription medicines, generating revenue when its products are ordered and reimbursed through pharmaceutical distribution channels. The company’s key revenue stream is net product sales (gross s...
Jazz Pharmaceuticals Earnings Call Summary
The call was strongly positive. Jazz reported record revenue, raised full-year revenue and gross-margin guidance, delivered strong growth across oncology and Xywav, and described an encouraging early launch for Ziihera supported by favorable clinical data and market access. The company also highlighted substantial cash generation, pipeline progress and the Actio acquisition. Offsetting factors included lower adjusted gross margin, a reported non-GAAP loss driven by the Actio acquired IPR&D charge, a measured near-term Modeyso revenue pace, and future competitive pressure for Zepzelca. The positive operating and strategic developments significantly outweighed the stated challenges.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, Jazz raised and narrowed total revenue guidance to a range of $4.775 billion to $4.85 billion, representing nearly 13% growth over 2025 at the midpoint; rare sleep revenue is now expected to be $2.125 billion to $2.175 billion, led by Xywav growth of low double digits to low teens, while non-GAAP gross margin guidance increased by 50 basis points to a range of 90.5% to 91.5%, non-GAAP effective tax rate guidance is a range of 19.5% to 21.5%, and share count guidance remains unchanged at 69 million to 70 million shares. Ziihera peak sales potential is a range of $3 billion to $5 billion, Modeyso has a $500 million peak expectation in the U.S., and Zepzelca is likely to face a future headwind in 2027.
Jazz Pharmaceuticals Financial Statement Overview
Summary
Strong cash generation is the key positive (TTM operating cash flow ~$1.69B and free cash flow ~$1.57B) alongside very strong gross margins (~85–89%). Offsetting this, profitability has been volatile (net loss in 2025, only modestly positive in TTM) and leverage remains elevated (TTM debt-to-equity ~1.35x), which constrains the balance-sheet profile.
Income Statement
67PositiveBalance Sheet
54NeutralCash Flow
81Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.72B | 4.27B | 4.07B | 3.83B | 3.66B | 3.09B |
| Gross Profit | 4.16B | 3.76B | 3.62B | 3.40B | 3.12B | 2.65B |
| EBITDA | 1.17B | 262.76M | 1.52B | 1.45B | 1.47B | 1.03B |
| Net Income | 205.95M | -356.15M | 560.12M | 414.83M | -224.06M | -328.95M |
Balance Sheet | ||||||
| Total Assets | 12.00B | 11.66B | 12.01B | 11.39B | 10.84B | 12.30B |
| Cash, Cash Equivalents and Short-Term Investments | 2.86B | 2.44B | 2.99B | 1.63B | 881.48M | 591.45M |
| Total Debt | 5.64B | 5.42B | 6.16B | 5.79B | 5.81B | 6.15B |
| Total Liabilities | 7.81B | 7.34B | 7.92B | 7.66B | 7.75B | 8.33B |
| Stockholders Equity | 4.19B | 4.32B | 4.09B | 3.74B | 3.09B | 3.97B |
Cash Flow | ||||||
| Free Cash Flow | 1.57B | 1.15B | 1.35B | 1.07B | 773.78M | 732.98M |
| Operating Cash Flow | 1.69B | 1.36B | 1.40B | 1.09B | 1.27B | 778.51M |
| Investing Cash Flow | -977.96M | -1.51B | -508.19M | -163.06M | -446.23M | -5.21B |
| Financing Cash Flow | -3.86M | -873.38M | 20.52M | -305.25M | -529.49M | 3.97B |
Jazz Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JAZZ, the sentiment is Positive. The current price of 240.71 is above the 20-day moving average (MA) of 224.78, above the 50-day MA of 228.99, and above the 200-day MA of 220.40, indicating a bullish trend. The MACD of 5.30 indicates Negative momentum. The RSI at 58.99 is Neutral, neither overbought nor oversold. The STOCH value of 68.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JAZZ.
Jazz Pharmaceuticals Risk Analysis
Jazz Pharmaceuticals disclosed 47 risk factors in its most recent earnings report. Jazz Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksJazz Pharmaceuticals Peers Comparison
Overall Rating
NBIX80Outperform
HRMY77Outperform
PRAX71Outperform
JAZZ67Neutral
AXSM47Neutral
XENE46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | $16.73B | 23.78 | 19.74% | ― | 37.98% | 61.95% | |
| 77Outperform | $1.94B | 10.73 | 18.55% | ― | 19.79% | -4.89% | |
| 71Outperform | $8.67B | -24.00 | -29.41% | ― | -100.00% | 0.75% | |
| 67Neutral | $15.39B | 67.29 | 4.62% | ― | 13.48% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | $7.21B | -45.12 | -189.73% | ― | 54.16% | 34.51% | |
| 46Neutral | $3.86B | -8.35 | -39.80% | ― | -100.00% | -21.09% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals | 240.71 | 64.63 | 36.70% | |
| NBIX | Neurocrine Biosciences | 165.92 | 27.86 | 20.18% | |
| XENE | Xenon Pharmaceuticals | 38.78 | -1.87 | -4.60% | |
| AXSM | Axsome Therapeutics Inc. | 135.95 | -10.82 | -7.37% | |
| HRMY | Harmony Biosciences Holdings, Inc. | 33.01 | -0.30 | -0.90% | |
| PRAX | Praxis Precision Medicines, Inc. | 305.06 | 115.74 | 61.13% |
Jazz Pharmaceuticals Corporate Events
Jazz Pharmaceuticals Plans Commercial Leadership Transition Ahead
NeutralOn October 6, 2026, Jazz Pharmaceuticals said Executive Vice President and Chief Commercial Officer Samantha Pearce plans to retire from her role no later than June 30, 2027, or earlier upon the appointment of her successor. The company will initiate...
Jazz Pharmaceuticals Refinances Term Loan, Extends Maturities
PositiveOn September 23, 2026, Jazz Financing Lux S.Ã r.l., a wholly owned subsidiary of Jazz Pharmaceuticals, entered into a fourth amendment to its existing credit agreement to extend the maturity and reprice its U.S. dollar term loan B-2 facility original...
Jazz Pharmaceuticals Acquires Actio Biosciences to Expand Epilepsy Portfolio
PositiveOn September 15, 2026, Jazz Pharmaceuticals completed its $820 million upfront acquisition of privately held Actio Biosciences, making Actio an indirect wholly owned subsidiary via a merger structure. As part of the deal, Actio’s non‑ABS‑1230 program...
Jazz Pharmaceuticals Completes $1.25 Billion Notes Offering
PositiveOn August 31, 2026, Jazz Investments I Limited, a wholly owned subsidiary of Jazz Pharmaceuticals, closed a private offering of $1.25 billion of 1.875% exchangeable senior notes due 2032 to qualified institutional buyers under Rule 144A, following fu...
Jazz wins FDA nod for Ziihera gastric cancer use
PositiveOn August 25, 2026, Jazz Pharmaceuticals said the U.S. Food and Drug Administration approved two Ziihera-containing regimens for first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarci...
Jazz Pharmaceuticals to Acquire Actio Biosciences in Merger
PositiveOn August 10, 2026, Jazz Pharmaceuticals, Inc. agreed to acquire Actio Biosciences, Inc. in a cash-based merger valued at an initial $820 million, with customary balance sheet adjustments, making Actio a wholly owned subsidiary. The deal structure co...
Jazz Pharmaceuticals to Acquire Rare Epilepsy Specialist Actio
PositiveOn August 10, 2026, Jazz Pharmaceuticals agreed to acquire privately held Actio Biosciences in a deal featuring an $820 million upfront payment and up to $500 million in milestone-based contingent consideration. The transaction, unanimously approved...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026
